Myriad Genetics detailed a menu refresh at JP Morgan, committing to launch tissue‑informed minimal residual disease (MRD) tests across breast, renal, colorectal, endometrial, and ovarian cancers over the next two years. CEO Sam Raha outlined a phased rollout beginning with a breast MRD assay in Q1 2026, MolDx coverage submissions in Q3 2026, and commercial launches into 2027. Myriad also plans AI‑enabled enhancements to its Prolaris prostate test and expanded hereditary cancer panels. The company emphasized clinical studies—over 20 MRD trials underway—to validate use cases and drive payer coverage. The roadmap signals intensified competition in MRD testing as diagnostic firms vie for clinical adoption and reimbursement in oncology monitoring and adjuvant decision‑making.